What We Do
From Market Intelligence to Market Presence
Our capabilities cover the full international commercialisation journey. Every engagement is shaped around your product, your market, and your objectives.
International Commercialisation
Bringing a pharmaceutical product into a new international market is rarely straightforward. Regulatory landscapes vary. Commercial relationships take time. The gap between product approval and commercial success is where most international expansions stall.
We support organisations through every stage: market assessment, strategic planning, partner identification, licensing coordination, commercial readiness, and in-market support. We are particularly effective in markets where relationships and trust matter as much as regulatory credentials.
What We Do
- •
International market entry strategy and planning
- •
Target market assessment and commercial feasibility
- •
Dossier alignment and regulatory environment navigation
- •
Partner identification and qualification
- •
Licensing and commercialisation agreement support
- •
Launch readiness and in-market support
- •
Long-term commercial relationship management
Who This Is For
- •
Manufacturers and dossier holders seeking robust routes into the GCC / MENA, or Greater China
- •
Enterprises seeking trusted, compliant partners to navigate and enter the UK and European markets
- •
Companies with approved products seeking a commercialisation partner
- •
Organisations navigating an international market for the first time
- •
Products with strong clinical data in one region and untapped commercial potential in others
Market Access, Licensing and Regulatory Coordination
Market access is where commercial ambition meets regulatory reality. It is also where the most value can be created or lost.
We work alongside manufacturers and their regulatory partners to coordinate licensing submissions, support registration planning, and develop market access strategies aligned with local payer and prescriber environments. Our experience covers MHRA and EMA pathways, GCC Ministry of Health processes, and NMPA coordination in China.
What We Do
- •
International licensing strategy and coordination
- •
Registration pathway planning across UK, EU, GCC, and China
- •
Regulatory partner identification and management
- •
Reimbursement and HTA strategy support
- •
Named patient and compassionate use programme coordination
- •
Orphan and special designation strategy
Therapeutic Area Depth
- •
CNS and Mental Health: complex reimbursement landscapes
- •
Oncology: access schemes, managed entry, and accelerated pathways
- •
Rare and Orphan Diseases: designation strategy across multiple jurisdictions
- •
Immunology and Biologics: biosimilar entry and reference product strategies
- •
Specialty Pharmaceuticals: niche positioning and targeted stakeholder engagement
Strategic Supply and Distribution
International pharmaceutical supply chains are complex and heavily regulated. Getting products across borders safely, compliantly, and efficiently requires specialist coordination and trusted partners at every stage.
We connect manufacturers with qualified distribution partners, manage the regulatory and logistical complexity of cross-border supply, and support long-term commercial supply arrangements. Our experience includes close collaboration with EU and India CDMOs, giving us hands-on knowledge of GMP compliance, batch release, and quality management systems. We also support cross-border trade facilitation across Asia Pacific through established regional networks.
What We Do
- •
Distribution partner identification and qualification
- •
Cross-border supply pathway coordination
- •
GDP-compliant supply chain management
- •
Cold chain and temperature-sensitive product coordination
- •
Import and export regulatory and documentation support
- •
Supply chain risk assessment
Our Supply Network
- •
Qualified distribution partners across UK and EU
- •
Dubai-centric hub logistics facilitating seamless GCC regional supply and warehousing coordination.
- •
Asia Pacific trade facilitation through deeply established regional networks
- •
Direct relationships with specialist 3PL and cold chain operators
- •
Strategic CDMO relationships across the EU and India for agile manufacturing coordination
Licensing and Product Portfolio Development
Lexigen is actively developing its own pipeline of specialty pharmaceutical products through strategic in-licensing partnerships and selective own-development programmes.
We have established a partnership focused on developing and commercialising niche specialty products for the UK and international markets. This is the long-term dimension of our platform, moving towards proprietary product development alongside our commercialisation work.
What We Do
- •
In-licensing opportunity identification and evaluation
- •
Licensing negotiation, asset acquisition, and agreement support
- •
Development programme oversight and scientific partner management
- •
Regulatory strategy for in-licensed and proprietary developed products
- •
Commercialisation planning for proprietary assets
- •
Strategic portfolio building across target therapeutic areas
Our Focus Areas
- •
CNS, Mental Health, and Rare Disease: Focusing on high unmet needs and complex access environments.
- •
Specialty Biologics and Innovative Formulations: Enhancing patient outcomes through smarter delivery mechanisms
- •
Established Assets: Geographically expanding proven European or UK portfolios into high-growth global corridors
- •
NNiche Products: Championing underserved therapeutics often overlooked by larger multi-nationals
- •
Value-Added Generics: Products approaching patent transition with distinct reformulation or repositioning potential
Ready to Explore What Is Possible?
Every engagement starts with a conversation. Tell us about your product, your market objectives, and the challenges you face. We will give you an honest assessment of how we can help.